The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Novel approaches in NSCLC
Alessandra Bearz, MD, CRO National Cancer Institute, Aviano, Italy, provides an overview of novel approaches in non-small cell lung cancer (NSCLC), including targeting resistance mechanisms, as well as combining targeting therapies and chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
